Answers are grounded in this paper and cite their sources.
Liver fibrosis is a wound-healing process where ECM accumulation occurs in the liver. It mainly occurs by inducing a variety of hepatotoxic agents, lipid decomposition, drugs, alcohol consumption, viruses, and autoimmune reactions. Among various processes, liver transplantation is the best way of treatment for patients in critical conditions. This transplantation process has various limitations. So, another mechanism is discovered, the name is cell-based therapy. Cell therapy using stem cells (from various sources) is an alternative approach for treating liver fibrosis. Transplanted mesenchymal stem cells could be a replacement for damaged hepatocytes. And it has the capacity to induce apoptosis of activated hepatocyte cells. This present review will go to balance the latest discoveries about mesenchymal stem cell-based therapies to treat liver fibrosis. All discoveries are in vivo experimentally proved and all studies with pre-clinical and clinical trials. Several studies suggest, in the world, that liver disease accounts for about 3-4% of death mesenchymal stem cells have the ability to reduce liver fibrosis and recover liver function.
No takes yet. Share an insight, caveat, or question.
Sarkar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: